Comparative Pharmacology
Head-to-head clinical analysis: BENZACLIN versus CLEOCIN T.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZACLIN versus CLEOCIN T.
BENZACLIN vs CLEOCIN T
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BENZACLIN (clindamycin 1% and benzoyl peroxide 5%) is a combination antibacterial agent. Clindamycin is a lincosamide antibiotic that binds to the 50S ribosomal subunit of bacteria, inhibiting protein synthesis and reducing Propionibacterium acnes growth. Benzoyl peroxide has bactericidal and keratolytic properties; it releases free radical oxygen species that oxidize bacterial proteins, decreasing P. acnes, and also causes drying and peeling of the skin.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, suppressing peptide bond formation. It exhibits bacteriostatic activity against susceptible organisms.
Topical gel applied once or twice daily to affected areas. Each gram contains 1% clindamycin and 5% benzoyl peroxide.
Apply a thin film of 1% solution or gel twice daily to affected skin areas.
None Documented
None Documented
After topical application, plasma concentrations of clindamycin are negligible; the systemic half-life of clindamycin from absorbed fraction is approximately 2.5-3 hours in adults. However, due to minimal systemic absorption, the terminal half-life is not clinically relevant for topical therapy.
The terminal elimination half-life in adults with normal renal and hepatic function is approximately 2-3 hours. In severe hepatic impairment, half-life may increase to 5-6 hours. No significant alteration in renal impairment.
Benzaclin (clindamycin 1% - benzoyl peroxide 5%) is a topical formulation; systemic absorption is minimal. After topical application, less than 1% of clindamycin is absorbed. Absorbed clindamycin is primarily excreted in urine (10% as active drug, 90% as metabolites) and feces (<5%). Benzoyl peroxide is metabolized to benzoic acid, which is conjugated and excreted in urine. Overall, renal excretion accounts for the majority of clearance of absorbed components.
Clindamycin is primarily eliminated via hepatic metabolism and biliary excretion. Approximately 10% of the active drug is excreted renally, with the remainder as inactive metabolites in feces (biliary/fecal route).
Category C
Category C
Topical Antibiotic
Topical Antibiotic